Clin2
NCT07216066Possibly a fitRecruiting

Study of ALN-SNCA for early Parkinson's disease

Parkinsons Disease

Part of Bones, joints & muscles, Brain & nervous system, Mental health clinical trials.

This trial tests a new experimental drug called ALN-SNCA, given as an injection into the spinal fluid, for people with early Parkinson's disease. The goal is to see if it is safe and well-tolerated.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
46 people
Ages
50 years to 80 years
Study type
Interventional

Who can take part

  • You have been diagnosed with Parkinson's disease within the last 4 years.
  • You either are not taking any Parkinson's medication, or you have been on a stable dose of medication for at least 3 months.
  • Your body mass index (BMI) is 35 or less.
  • You do not have any other serious medical condition that could affect the study results (like heart, lung, liver, or kidney disease).
  • You are able to have a lumbar puncture (spinal tap) and an MRI safely.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07781644Not yet recruiting· Phase 1/Phase 2
Testing a new drug for early Parkinson's disease

This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.

NCT07585565Not yet recruiting· Phase 2
Study of a new injection for Parkinson's motor fluctuations

This trial tests an injection that may help reduce Parkinson's symptoms when they fluctuate, such as when medication wears off. It is for people who are already taking levodopa but still have periods of poor symptom control.

NCT06565195Recruiting· Phase 1
Study of an investigational drug for Parkinson's disease

This study tests an experimental drug called LY3962681 in two groups: healthy volunteers and people with Parkinson's disease. The goal is to see if the drug is safe and how the body handles it, which may lead to future treatments for Parkinson's.

Englewood, Colorado
NCT06175767Not yet recruiting· Phase 2
Early Parkinson's disease trial for new drug MT101-5

This study tests an investigational drug called MT101-5 for people with early Parkinson's disease. The goal is to see if it is safe and can help slow the progression of symptoms.

NCT07214727Recruiting· Phase 1
A study of ALN-5288 for Alzheimer's disease

This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.

Montreal
NCT07212088Not yet recruiting· Phase 1
Brain cell injection study for Parkinson's disease

This study tests a new treatment for Parkinson's disease where special cells are injected directly into the brain. It aims to reduce 'off' time and improve movement control for people who have had Parkinson's for over 5 years and take levodopa but still experience daily complications.

Hangzhou, Zhejiang

Hear when a new Parkinson’s disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.